• Vivoryon Therapeutics reported a net loss of EUR 3.4 million, narrowing from EUR 5.5 million in the year-earlier period.
• Operating loss narrowed to EUR 3.39 million from EUR 5.52 million, while revenue remained at no revenue.
• R&D expenses fell 39.92% to EUR 1.7 million, due to lower kidney clinical development costs plus reduced patent and consulting fees.
• G&A expenses dropped 39.09% to EUR 1.7 million on lower non-cash share-based personnel costs plus reduced legal spending.
• Cash and cash equivalents slid to EUR 2.4 million from EUR 5.6 million at Dec. 31, 2025; cash runway guidance stays into Q4 2026.
• Advanced term-sheet talks for a potential kidney-disease licensing deal continue, with a specialist investor assessing varoglutamstat for a potential investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivoryon Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608060100OMX_____CNEWS_EN_GNW1001256306_en) on August 06, 2026, and is solely responsible for the information contained therein.